These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11741248)

  • 1. Nonlinearity detection: advantages of nonlinear mixed-effects modeling.
    Jonsson EN; Wade JR; Karlsson MO
    AAPS PharmSci; 2000; 2(3):E32. PubMed ID: 11741248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model.
    Bach T; An G
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):581-595. PubMed ID: 33884580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fast method for testing covariates in population PK/PD Models.
    Khandelwal A; Harling K; Jonsson EN; Hooker AC; Karlsson MO
    AAPS J; 2011 Sep; 13(3):464-72. PubMed ID: 21725709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
    Bazzoli C; Retout S; Mentré F
    Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of different population pharmacokinetic algorithms.
    Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP
    Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exact Gradients Improve Parameter Estimation in Nonlinear Mixed Effects Models with Stochastic Dynamics.
    Olafsdottir HK; Leander J; Almquist J; Jirstrand M
    AAPS J; 2018 Aug; 20(5):88. PubMed ID: 30069613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the nonparametric estimation method in NONMEM VI.
    Savic RM; Kjellsson MC; Karlsson MO
    Eur J Pharm Sci; 2009 Apr; 37(1):27-35. PubMed ID: 19159684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.
    Hooker AC; Staatz CE; Karlsson MO
    Pharm Res; 2007 Dec; 24(12):2187-97. PubMed ID: 17612795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.
    Bauer RJ; Guzy S; Ng C
    AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.
    Liu X; Wang Y
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):359-70. PubMed ID: 27215925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to handling pharmacodynamic baseline responses.
    Dansirikul C; Silber HE; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):269-83. PubMed ID: 18446428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using sensitivity equations for computing gradients of the FOCE and FOCEI approximations to the population likelihood.
    Almquist J; Leander J; Jirstrand M
    J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):191-209. PubMed ID: 25801663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.
    McGree JM; Eccleston JA; Duffull SB
    J Pharmacokinet Pharmacodyn; 2009 Apr; 36(2):101-23. PubMed ID: 19224348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonlinear mixed effects to improve glucose minimal model parameter estimation: a simulation study in intensive and sparse sampling.
    Denti P; Bertoldo A; Vicini P; Cobelli C
    IEEE Trans Biomed Eng; 2009 Sep; 56(9):2156-66. PubMed ID: 19380266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-linear mixed-effects models with stochastic differential equations: implementation of an estimation algorithm.
    Overgaard RV; Jonsson N; Tornøe CW; Madsen H
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):85-107. PubMed ID: 16175312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of actual significance levels for covariate effects in NONMEM.
    Wählby U; Jonsson EN; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):231-52. PubMed ID: 11468939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Derivation of various NONMEM estimation methods.
    Wang Y
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):575-93. PubMed ID: 17620001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of uncertainty parameters estimated by different population PK software and methods.
    Dartois C; Lemenuel-Diot A; Laveille C; Tranchand B; Tod M; Girard P
    J Pharmacokinet Pharmacodyn; 2007 Jun; 34(3):289-311. PubMed ID: 17216368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linear mixed-effect multivariate adaptive regression splines applied to nonlinear pharmacokinetics data.
    Gries JM; Verotta D
    J Biopharm Stat; 2000 Aug; 10(3):383-98. PubMed ID: 10959918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.